Keywords: Silence Therapeutics, RNAi, AstraZeneca, Dainippon Sumitomo, Novartis
Silence Thera receives takeover approach from unnamed drug firm
Article | 07 September 2010
UK-based drug developer Silence Therapeutics (AIM: SLN) saw its share price skyrocket 76% to 12.75 pence by close of London trading yesterday, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
